Clinical Trial Supply China 2026 中国临床试验供应链大会

Clinical Trial Supply China is returning for a second year! This is your gateway to understanding and excelling in the rapidly evolving landscape of clinical trial logistics in China.
中国临床试验供应链大会第二年重磅回归！这是您了解并在中国快速发展的临床试验供应链领域脱颖而出的绝佳机会。

8 - 9

September

2026
  • Renaissance Suzhou Hotel
  • Ticketed
  • Why attend?
  • Agenda
  • Plan Your Visit
  • Sponsors
  • Media Centre
  • Why partner?
  • Contact Us
close

Sponsors Include:

Back

Company Information

ARENSIA Exploratory Medicine, a German-based company, is a leader in “first-in-patient” Phase IB and II/Proof-of-Concept clinical trials across a wide range of disease areas. With 14 proprietary research clinics and cutting-edge Phase I infrastructure, ARENSIA accelerates the early detection of efficacy signals for new therapies at an unparalleled speed. Its streamlined, highly efficient approach reduces patient recruitment time and costs by over 50% compared to conventional trial sites, which are often overcrowded and understaffed. This exceptional performance has resulted in a 93% repeat business rate and robust growth through collaborations with top pharmaceutical companies, biotechs, and global CROs. Headquartered in Düsseldorf, ARENSIA operates with a team of 600 professionals across 8 countries.

Company Website

To learn more, please visit our website - http://www.arensia-em.com/

Next Sponsor
Back

Company Information

Nucleus Network is Australia’s largest Phase 1 clinical research organisation and the only Phase 1 specialist globally with phase I facilities in the US and Australia. 

Our Australian phase I facilities are in Melbourne and Brisbane, and our US phase I facility is located in Minneapolis. Combined, our clinics offer over 200 beds. All three clinics are strategically co-located within leading medical, research and biotech precincts offering unique access to ancillary services including bioanalytical laboratories, MRI, lumbar punctures, chest X-rays, ophthalmology assessments and others. 

Since our establishment in 2004, we have conducted over 700 phase I clinical trials, with 80% of our clients consisting of US based biotech and pharmaceutical companies. 

We have access to a population of over 10.5 million people across all 3 sites, and the ability to offer a multi-site solution in recruiting participants and patients to our clients. 

Together with our client partners, we are fulfilling our purpose of ‘Advancing medicine, improving lives.’

Company Website

To learn more, please visit our website - https://www.nucleusnetwork.com/au/

Next Sponsor
Back

Company Information

Akesa is an end-to-end provider of clinical trial supplies and services. Headquartered in Melbourne, Australia, Akesa boasts global reach with deep expertise in the Asia-Pacific region. We work alongside sponsors, CROs, research institutions, clinical trial sites and CDMOs to project manage the sourcing of finished products, including comparators, combination therapies, and standard-of-care medications, from validated suppliers and directly from manufacturers.

Company Website

To learn more, please visit our website - http://akesapharma.com/

Next Sponsor
Back

Company Information

We’re more than a supplier: we’re a partner that can deliver consistent quality and superior service, a partner that fuels innovation to foster real and sustainable results. A deep understanding of the healthcare industry, our customers’ needs, and patient needs is critical to ensure our range of packaging products and services deliver value through the entire product lifecycle. These insights and the experience of the Smurfit Westrock Adherence & Clinicals team enable us to work in tune with regulations and clients to provide a service solution underpinned by an innovative and unparalleled range of packaging solutions that, at their heart, are patient focused. These include Clinical Trial Packaging, specialty labels, literature & booklets, Adherence packaging, component kits and SMART Digital Adherence Technology along with Digital Display Labels. Talk to us.

www.smurfitwestrock.com

Next Sponsor
Back

Company Information

We are a global operational consulting firm helping Life Science companies stay compliant and inspection-ready. We specialize in Data Privacy (GDPR and global regulations), GxP Quality, and Computer System Validation. With senior-level experts across the EU, UK, and beyond, we support over 90 clients worldwide through audits, legal representation, and compliance excellence.

Company Website

To learn more, please visit our website - www.pharmarketing.net

Next Sponsor
Back

Company Information

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

Company Website

To learn more, please visit our website - www.novotech-cro.com

Next Sponsor
Back

Company Information

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground” patient recruitment experts in over 70 countries, addressing individual sites’ unique patient recruitment and retention challenges in local language. Innovative Trials has experience in 25 therapeutic areas and 90+ conditions.

Company Website

To learn more, please visit our website - https://innovativetrials.com/

Next Sponsor
Back

Company Information

Euromed Pharma deliver strategic services tailored to support companies in their quest to better healthcare. We support each industry player from drug development through the post-marketing phases. We offer solutions in CTS services, Clinical GMP Packaging, Labeling and Distribution, IMP management, Early Access and Named Patient Programs, Pharma Order to cash solutions, and Supply Chain & Logistics. We are present around the world with offices in Italy, Spain, Ireland, Germany, Singapore and the USA. Being one of the Petrone Group companies, Euromed Pharma is positioned at the forefront of innovation in pharmaceutical distribution.

Company Website

To learn more, please visit our website - www.euromed-pharma.com

Next Sponsor

    Why attend?

    Why attend? 为何参会？

    Navigate Local Challenges: Gain critical insights into the unique complexities of clinical trial supply chains in China, including import/export regulations, regional distribution, and local manufacturing.

    破解本土化难题
    深度解析中国临床试验供应链特有的复杂挑战，包括进出口监管政策、区域配送网络布局及本土化生产策略等核心议题。

    Regulatory Expertise: Stay updated on China’s regulatory environment, ensuring compliance while minimizing delays and risks in your clinical trial supply processes.

    掌握监管先机
    实时获取中国药监动态，系统学习如何在确保合规前提下，规避供应链延误风险与质量隐患。

    Build Strategic Partnerships: Connect with key stakeholders, including suppliers, logistics providers, and biopharmaceutical companies, to foster collaborations that drive efficiency and innovation.

    缔造战略联盟
    与供应链核心决策者直接对话：包括头部物流服务商、本土供应商及跨国药企供应链负责人，构建高效协同网络。

    Discover Innovative Solutions: Explore cutting-edge tools, technologies, and strategies to optimize supply chain management, ensure product integrity, and reduce operational costs.

    解锁创新方案
    探索保障产品完整性的前沿技术：从智能温控物流系统到区块链追溯平台，获取降本增效的实战解决方案

    Stay Ahead of Trends: Learn about emerging trends and future directions in clinical trial supply tailored specifically to the Chinese market.

    洞见未来趋势
    聚焦中国市场独有的发展趋势：从MAH制度下的供应链重构到临床急需药物特殊通道，把握政策红利窗口期

    Whether you’re launching trials in China or looking to refine your supply chain operations, this conference provides the knowledge and connections you need to thrive in one of the most dynamic markets for clinical trials.

    无论您是首次在中国开展临床试验，还是寻求优化现有供应链体系，本次大会都将为您提供在这个最具活力的临床试验市场中蓬勃发展所需的关键洞见与战略人脉。

    Agenda

    • 8 Sep 2026
    • 9 Sep 2026
    Expand All

    8 AM

    Registration and refreshments 注册签到与晨间茶歇

    8:50 AM

    Chairperson’s opening remarks 主席开幕致辞

    9 AM

    OPENING KEYNOTE: China’s Biopharma Leap: From Fast-Follower to Global Innovator 开幕主旨演讲：中国生物医药的跨越——从快速跟跑到全球创新

    China stands at an inflection point in global biopharma innovation. Having mastered the art of rapid development and commercialization as a fast-follower, the industry is now making a decisive strategic pivot towards becoming a true global innovator. The rise of China-led international multi-center trials (MRCTs) and landmark global partnerships underscores a new reality: China is no longer just a vast market or a development executor, but a primary source of scientific insight and therapeutic value.

    • From “Fast Follower” to Autonomous Innovation
    • Leveraging China’s Capabilities for Worldwide Development
    • From Local Assurance to Global Collaboration
    • Aligning Standards and Achieving Mutual Recognition
    • Building an Open, Collaborative Global Network

    中国正处于全球生物医药创新的关键转折点。作为快速跟跑者，中国已熟练掌握快速研发与商业化的核心能力，如今正坚定地向真正的全球创新者战略转型。中国主导的国际多中心临床试验的崛起，以及里程碑式的全球合作伙伴关系，揭示了一个全新的现实：中国不再仅仅是一个广阔的市场或研发执行方，而正在成为科学洞见与治疗价值的重要源头。

    •  从“快速跟跑”到自主创新
    •  借力中国能力赋能全球研发
    •  从本土保障到全球协作
    •  标准互认与监管对齐
    •  构建开放协作的全球创新网络

    9:30 AM

    Reserved for Sponsor 供应商专场

    10 AM

    KEYNOTE PANEL: The Patient Enrollment Revolution: Global Lessons from China’s Clinical Trial Efficiency 主旨圆桌：患者入组革命——中国临床试验效率的全球启示

    Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution.

    • How China Building Beyond "Population Advantage"
    • How to Leverage AI and Digital Platforms in Patient Matching
    • The Power of Hospital Alliances and Regional Clinical Hubs
    • What are the most effective patient-centric strategies to ensure trial success?
    • How to Adapt China’s Model for International Multi-Center Trials

    患者入组仍然是全球药物研发中最关键的瓶颈之一，常常导致周期延误、成本攀升，并限制患者对创新疗法的可及性。在这一背景下，中国不仅凭借庞大的患者基数脱颖而出，更成为临床试验执行层面系统性创新的试验田。

    • 中国如何超越“人口红利”构建系统性优势
    • 如何利用人工智能与数字平台实现患者精准匹配
    • 医院联盟与区域临床中心的核心驱动力
    • 确保试验成功的患者中心策略有哪些有效实践
    • 如何将中国模式适配应用于国际多中心试验

    10:30 AM

    Morning refreshments and networking 上午茶歇及交流

    (Visit 3 booth at least)

    （请访问至少3个展台）

    11 AM

    The Intelligent Cold Chain: How Precision Logistics Are Unlocking Global Trials for Next-Generation Therapies 智能冷链：精准物流如何解锁下一代疗法的全球试验

    The advent of “living drugs” has made the clinical supply chain a critical factor in clinical trial success, requiring a shift from basic cold chain to data-driven precision logistics. Integrating digital intelligence into the cold chain is now essential, transforming it into a robust platform that ensures the reliable and scalable global delivery of these complex therapies.

    • From Passive Shipping to Active, Intelligent Orchestration
    • IoT, Blockchain, and the Creation of a "Digital Twin" for Every Shipment
    • Using AI to Forecast and Prevent Deviations
    • Closing the Loop from Vein-to-Vein
    • ROI on Intelligence in Risk Reduction and Speed

    “活药物”时代的到来，使临床供应链从后台支持跃升为决定试验成败的关键变量。我们正面临从基础冷链向数据驱动的精准物流的根本转型。将数字智能深度整合进冷链不再是锦上添花，而是必答题——它正将脆弱的物流环节重塑为支持复杂疗法全球规模化交付的可靠平台。

    • 从被动运输到主动智能协同
    • 物联网、区块链与每一批次的“数字孪生”
    • 利用人工智能预测并规避温控偏差
    • 从静脉到静脉的全流程闭环管理
    • 智能冷链在风险降低与速度提升中的投资回报

    11:30 AM

    Reserved for Sponsor 供应商专场

    12 PM

    Localization Strategy: Balancing Import Efficiency with Domestic Manufacturing 本土化战略：进口效率与国产制造的动态平衡

    The global clinical supply chain faces a pivotal shift as the traditional model of centralized manufacturing is strained by geopolitical, trade, and pandemic-related disruptions. This necessitates a strategic move towards resilient and nuanced localized supply approaches to meet modern clinical trial demands.

    • From Global Efficiency to Regional Resilience
    • Designing Your Multi-Tiered Supply Footprint
    • From "World Factory" to "Innovation Partner"
    • Ensuring Visibility and Control Across a Distributed Network
    • Collaborative Models for Sustainable Success

    全球临床供应链正站在战略转折点上。长期依赖集中式生产的传统模式在地缘政治、贸易摩擦和疫情冲击下暴露出深层脆弱性。这迫使行业向更具韧性的战略本土化转型——不是简单替代，而是精妙平衡，以满足现代临床试验的复杂需求。

    • 从全球效率到区域韧性
    • 设计你的多层级供应网络布局
    • 从“世界工厂”到“创新伙伴”
    • 分布式网络下的全程可视与精准管控
    • 可持续成功的协同合作模式

    12:30 PM

    Reserved for Sponsor 供应商专场

    1 PM

    Lunch and networking 午餐及交流

    2:30 PM

    Supply Chain Readiness for Cell and Gene Therapy Trials in China 细胞与基因治疗试验的中国供应链承载能力

    The rise of Cell and Gene Therapies presents a formidable supply chain challenge due to their nature as "living drugs." Success in China's CGT clinical trials thus hinges on mastering a complex, time-sensitive, and patient-centric logistical system to translate the immense potential of these therapies into reliable patient outcomes.

    What is the Unique CGT Challenge
    Assessing China's Readiness in Cryogenic Logistics, GMP Facilities & Single-Use Technologies
    Orchestrating the "Vein-to-Vein" Journey with Real-Time Tracking & Chain of Custody
    Navigating NMPA Guidelines and Building QMS for Advanced Therapies
    The Integrated Role of Specialized CDMOs, Logistics Providers & Clinical Sites

    细胞与基因治疗的兴起对供应链提出了前所未有的挑战。作为“活药物”，其成功不仅取决于科学突破，更依赖于对高时效、个性化、零误差的复杂物流体系的全盘掌控，从而将这些疗法的巨大潜力转化为可靠的患者获益。

    • 理解CGT供应链的独特性挑战
    • 中国在深冷物流、GMP设施与一次性技术领域的准备度评估
    • 实时追踪与监管链：“静脉到静脉”全程协同
    • NMPA指南解读与先进疗法质量管理体系建设
    • 整合型CDMO、物流伙伴与临床中心的协作模式

    3 PM

    Reserved for Sponsor 供应商专场

    3:30 PM

    Managing Complex Logistics for ADC and Bi-Specific Antibody Clinical Trials ADC与双抗临床试验的复杂物流管理

    Antibody-Drug Conjugates (ADCs) and Bi-Specific Antibodies (BsAbs) represent the cutting edge of targeted oncology therapeutics. The delicate balance of the ADC structure (linker, antibody, payload) and the intricate assembly of the BsAb (two distinct binding domains) impose unprecedented demands for coordination and control across every logistical step, from manufacturing to the patient's bedside.

    • Identifying Critical Vulnerabilities in ADC & BsAb Supply Chains
    • Strategies from Point-of-Manufacture to Global Distribution
    • How to Leverage IoT and Blockchain for End-to-End Traceability from Factory to Bedside
    • Dynamic Strategies for Dose Escalation & Biomarker-Driven Patient Stratification
    • Leveraging China's Mature Biologics Supply Chain Ecosystem

    抗体偶联药物（ADC）和双特异性抗体（BsAb）代表了肿瘤靶向治疗的最前沿。ADC结构的精妙平衡（连接子、抗体、有效载荷）与BsAb的复杂组装（两个不同的结合域），对从生产到患者床边的每一个物流环节都提出了前所未有的协同与控制要求。

    • 识别ADC与双抗供应链的关键脆弱点
    • 从生产端到全球分销的策略布局
    • 如何利用物联网和区块链实现从工厂到床边的端到端可追溯
    • 剂量递增与生物标志物驱动患者分层的动态应对策略
    • 借力中国成熟的生物制剂供应链生态

    4 PM

    Afternoon refreshments and networking 下午茶歇及交流

    4:30 PM

    Comparator Sourcing: Navigating Global Supply for China Registration Trials 对照药采购：为中国注册临床试验导航全球供应链

    Securing the right comparator drug is often the most critical yet daunting hurdle in planning a registration trial in China. Unlike other supplies, a comparator is not merely a commodity; it is a regulatory benchmark, a clinical necessity, and a potential bottleneck that can derail timelines and compromise data integrity.

    • Why Compliance is Non-Negotiable
    • From Global Market to Local Solutions
    • Mastering the Logistics & Regulatory Journey
    • How to ensure Supply Continuity
    • What is the Evolving Landscape in the Future

    在中国注册临床试验的筹备过程中，寻获合适的对照药往往是最关键却又最棘手的关卡。与其它试验物资不同，对照药远非普通商品——它是监管审评的标尺，是临床设计的刚需，更是随时可能拖垮进度、危及数据完整性的潜在瓶颈。

    • 从全球采购到本土化解决方案
    • 通关物流与法规路径的全流程掌控
    • 如何确保供应不间断
    • 未来格局将如何演变

    5 PM

    PANEL DISCUSSION: Platform Strategies: Designing Flexible Supply Chains for Multi-Modality Trials 圆桌讨论：平台化战略——为多疗法组合试验设计柔性供应链

    A single biopharma portfolio today may encompass a diverse mix of modalities—small molecules, monoclonal antibodies, ADCs, cell therapies, and more—each with vastly different and often contradictory supply chain requirements. This new reality demands a fundamental shift towards platform-based supply chain strategies.

    • What Are We Actually Building?
    • Orchestrating Complexity with Data & AI
    • From Transactional Vendors to Strategic Capability Partners
    • Upskilling Teams for a Multi-Modality World
    • How to Measure Success?

    当今一个生物医药研发管线往往涵盖小分子、单抗、ADC、细胞疗法等多种药物类型，彼此的供应链要求差异巨大，甚至相互矛盾。这一新常态倒逼行业向“平台化供应链”战略根本转型。

    • 我们到底在搭建什么？
    • 用数据与人工智能调度复杂系统
    • 从“买卖供应商”到“战略能力合伙人”
    • 为多疗法时代重塑团队能力
    • 成功的衡量标准

    5:30 PM

    Chairperson’s closing remarks and Drinks Reception Sponsored 主席闭会致辞

    8 AM

    Registration and refreshments 注册签到与晨间茶歇

    8:50 AM

    Chairperson’s opening remarks 主席开幕致辞

    9 AM

    Supply Chain Resilience by Design 设计构建供应链韧性

    • What is the Strategic Blueprints
    • How to Make the Risk-informed Node Strategy
    • Dynamic Sourcing & Stocking Strategy
    • Partnering for Resilience
    • 战略蓝图是什么
    • 如何制定风险感知型节点布局策略
    • 动态采购与库存策略
    • 携手伙伴，共筑韧性

    9:30 AM

    Reserved for Sponsor 供应商专场

    10 AM

    Dynamic Forecasting for Rapidly Enrolling Trials 快速入组试验的动态预测

    Exploring agile forecasting strategies that enable clinical supply teams to respond in real time to fast recruitment rates, minimising risk, waste, and patient disruption.

    • Why Speed Creates a New Breed of Supply Chain Risk
    • How to Leverage Real-Time Enrollment Analytics and Site Intelligence
    • From Flexible Packaging to Just-in-Time Manufacturing
    • The Regulatory-Planning Nexus: Aligning with China's Accelerated Pathways
    • How to build Collaborative Ecosystem Orchestration

    中国无与伦比的患者招募速度，已将其推升为临床试验不可或缺的加速引擎。然而，那些建立在线性假设与滞后数据之上的传统需求预测模型，在中国临床生态的动态现实面前不堪一击。

    • 速度为何催生全新供应链风险
    • 如何活用实时入组数据与中心情报
    • 从柔性包装到即时生产
    • 监管与计划的交汇点：对齐中国加速审批路径
    • 如何构建协同生态的全局调度能力

    10:30 AM

    Morning refreshments and networking 上午茶歇及交流

    （请访问至少3个展台）

    11:15 AM

    Quality Management: Maintaining GMP Standards Across Complex Supply Networks 质量管理：在复杂供应网络中维护GMP标准

    Ensuring end-to-end compliance with Good Manufacturing Practice (GMP) standards is arguably the most significant operational challenge for sponsors and CDMOs alike. This complexity is heightened by the reality that a clinical supply network being a potential point of failure, not only for product quality but for the integrity of the entire trial.

    • Rethinking the Role of the Quality Unit
    • Risk-Based Supplier Qualification and Lifecycle Management
    • Digital Platforms for End-to-End Quality Data Integrity
    • Managing Change in a Distributed Network
    • Building a Culture of Quality Across Organizational Boundaries

    确保端到端合规、始终遵循药品生产质量管理规范（GMP），或许是申办方与CDMO共同面对的最大运营挑战。更棘手的是，临床供应网络的任何一环出现纰漏，不仅可能危及产品质量，更可能动摇整项试验的数据完整性。

    • 质量部门的角色需要重新定义
    • 基于风险的供应商资格认定与全生命周期管理
    • 端到端质量数据完整性的数字化平台支撑
    • 分布式网络下的变更如何管理
    • 跨越组织边界的质量文化建设

    11:45 AM

    PANEL DISCUSSION: Turning Transit Troubles into Triumphs: Proven Strategies for Clinical Supply Success 圆桌讨论：从运输困局到供应胜局——临床供应成功的实战策略

    • How to build a "Predict and Prevent" Supply Mindset
    • Dynamic Re-supply Models for a Dynamic Clinical Reality
    • A Step-by-Step Guide to Smoother Cross-Border Movements
    • Rapid Response Protocols and Effective Contingency Planning
    • Integrating Partners into a Single, Seamless Team
    • 如何建立“预测即预防”的供应思维
    • 动态临床现实下的动态补货模式
    • 跨境通关顺畅无阻的分步指南
    • 快速响应机制与高效应急预案
    • 无缝协同的团队的打造

    12:30 PM

    Lunch and networking 午餐及交流

    2 PM

    PANEL DISCUSSION Vision for the Future: The Future Roadmap of China’s Pharmaceutical Innovation 圆桌讨论：远见·未来：中国医药创新的征程与路线图

    China’s pharmaceutical innovation stands at a pivotal inflection point. After a decade of explosive growth, the industry is navigating a period of “capital winter,” intense policy-driven competition, and a strategic shift from the pursuit of quantity to the mandate of quality. However, this pressure is also a catalyst, forcing a clear-eyed re-evaluation of the path forward. Today, China is not just a vast clinical trial hub or a manufacturing powerhouse; it is defining its ambition to become a “world new drug creation center” by 2035.

    • The “Innovation Pivot”: From Fast-Follower to First-in-Class
    • The “Globalization 2.0” Playbook: From BD Transactions to Enduring Value
    • The “Dual Engine” of Policy: Regulatory Acceleration Meets Payment Reformation
    • Convergence and Concentration: Surviving the “Great Integration”
    • The Ultimate Alignment: Bridging the Pipeline to Unmet Clinical Need

    中国医药创新正站在一个关键的历史转折点。经历十年高速发展之后，行业步入“资本寒冬”，政策驱动的同质化竞争日趋激烈，发展逻辑正从追求数量向锚定质量深刻转型。然而，压力亦是催化剂，正倒逼全行业以更清醒的姿态重新审视前路。今天，中国不再仅仅是全球临床试验的聚集地或制药生产基地，它正在以2035年建成“世界级新药创制中心”为愿景，重新定义自己的全球坐标。

    • 创新力的转向：从快速跟跑到全球首创
    • 全球化2.0剧本：从授权交易到持久价值
    • 政策双引擎：监管提速与支付改革的同频共振
    • 收敛与集中：如何在“大整合期”存活并胜出
    • 终极对齐：让管线与未满足的临床需求精准接驳

    2:45 PM

    Speaker Hosted Roundtables 专家主持圆桌讨论

    Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

    Roundtable session lasts for 30 minutes and rotate

    ROUNDTABLE 1: How do we measure and incentivize long-term patient engagement and retention beyond the duration of a single trial?

    ROUNDTABLE 2: How do we transition from a cost-center logistics function to a value-creating strategic asset?

    ROUNDTABLE 3: What will it take for a Chinese company to be perceived as a peer and leader by the global biopharma ecosystem?

     

    互动式圆桌讨论为您提供一个与同行深度交流的独特机会，共同分享最佳实践，探讨行业面临的共性挑战并寻求解决方案。每场圆桌由行业专家主持，聚焦单一议题，以高互动性的形式助您拓展人脉网络，汲取同侪的经验与洞见。

    每场圆桌讨论时长为30分钟，设有轮换环节。

    圆桌讨论1

    单次试验结束后，我们如何衡量并激励患者的长期参与和保留？

    圆桌讨论2

    物流职能如何从“成本中心”转型为“价值创造型战略资产”？

    圆桌讨论3

    中国公司如何被全球生物医药生态视为平起平坐的同行乃至领导者？

    4 PM

    Lucky Draw & Chairperson’s closing remarks

    END OF CONFERENCE 会议结束

    Plan Your Visit

    Renaissance Suzhou Hotel

    Book Your Stay

    Arena International Events Group “(Arena”) is aware of numerous third-party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings, events attendee lists and selling unsolicited services. It is unclear whether the agencies in question are in possession of such information, or whether they intend to scam unsuspecting customers. Whilst Arena International Events Group pursues such third-party companies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third-party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

    Sponsors

    Select a sponsor to learn more

    Featured Sponsor

    Session Sponsor

    Technology Showcase Sponsor

    Exhibitor

    Why partner?

     

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 150+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Media Centre

    Media Partners

    Become A Media Partner

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Jarvinder Sidhu

    Senior Sales Executive

    +44 207947 2755

    SPEAKER ENQUIRIES

    Elyn Jiang

    Program Manager

    MARKETING ENQUIRIES

    Elyn Jiang

    Program Manager

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    Sponsorship Enquiries

     

    Jarvinder Sidhu

    Senior Sales Executive


    +44 207947 2755

    Speaker Enquiries

     

    Maya Hudson

    Deputy Head of Production


    +44 204540 7766